CRAIG E. METROKA, M.D., PH.D.; ANNE MOORE, M.D.; JOSEPH A. SONNABEND, M.B.; SUSANNA CUNNINGHAM-RUNDLES, PH.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: Recently, danazol (Danocrine; Winthrop Laboratories, New York, New York) has been reported to decrease the need for transfusions of plasma products in persons with classic hemophilia and hemophilia B (Christmas disease) (1), to increase the platelet count in patients with autoimmune thrombocytopenic purpura (2), and to restore the T4/T8 ratio and lymphoproliferative responses to normal in patients with autoimmune thrombocytopenic purpura (3; FISCHL M. Personal communication.). These observations prompted us to examine the possibility that danazol might be able to improve T-cell function in patients with untreated Kaposi's sarcoma and persons who had clinically recovered from an
METROKA CE, MOORE A, SONNABEND JA, et al. Risks with Danazol in the Acquired Immunodeficiency Syndrome. Ann Intern Med. 1984;101:564–565. doi: 10.7326/0003-4819-101-4-564_2
Download citation file:
Published: Ann Intern Med. 1984;101(4):564-565.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use